Cargando…
Intratumor Heterogeneity of MYO18A and FBXW7 Variants Impact the Clinical Outcome of Stage III Colorectal Cancer
Many studies failed to demonstrate benefit from the addition of targeted agents to current standard adjuvant FOLFOX chemotherapy in stage III colorectal cancer (CRC) patients. Intratumor heterogeneity may foster the resistant subclones and leads to cancer recurrence. Here, we built a cancer evolutio...
Autores principales: | Lin, Peng-Chan, Yeh, Yu-Min, Lin, Bo-Wen, Lin, Shao-Chieh, Chan, Ren-Hao, Chen, Po-Chuan, Shen, Meng-Ru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658598/ https://www.ncbi.nlm.nih.gov/pubmed/33194745 http://dx.doi.org/10.3389/fonc.2020.588557 |
Ejemplares similares
-
Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer
por: Chan, Ren-Hao, et al.
Publicado: (2021) -
Prediction value of (18)F-FDG PET/CT intratumor metabolic heterogeneity parameters for recurrence after radical surgery of stage II/III colorectal cancer
por: Liu, Xin, et al.
Publicado: (2022) -
Measuring Intratumoral Heterogeneity of Immune Repertoires
por: Yuzhakova, Diana Vladimirovna, et al.
Publicado: (2020) -
Intratumor Heterogeneity in Early Lung Adenocarcinoma
por: Senosain, Maria-Fernanda, et al.
Publicado: (2020) -
Predictive value of intratumoral-metabolic heterogeneity derived from (18)F-FDG PET/CT in distinguishing microsatellite instability status of colorectal carcinoma
por: Zhang, Li, et al.
Publicado: (2023)